Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
New research shows that the occurrence of narcolepsy in China is highly correlated to a seasonal pattern, with onset most frequent in April.
The onset of narcolepsy appears to follow seasonal patterns of H1N1 and other upper airway infections, according to a new study of patients in China that was led by Stanford University School of Medicine narcolepsy expert Emmanuel Mignot, MD.
When the influenza A (H1N1) virus swept around the world in spring 2009, infection was presumed to be more common in immunosuppressed patients, such as those who have had a kidney transplant. Later that year, the International Societies of Transplantation recommended that transplant recipients receive at least one dose of the H1N1 vaccine, although there was no information on the efficacy of the vaccine in that population.
According to a new survey despite recent improvements in influenza vaccination rates among U.S. health care personnel, their rates for the 2010-2011 flu season still fell short of national health objectives.
CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.
The last century has seen two major pandemics caused by the H1N1 virus - the Spanish Flu in 1918 and 2009's Swine Flu scare, which had thousands travelling with surgical masks and clamoring for vaccination. But scientists did not know what distinguished the Swine Flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations.
In a new development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.
"The World Health Organization is declaring an end to the global swine flu pandemic," the Associated Press/Seattle Times reports.
From Iowa to Brazil, researchers are discovering there is a distinct association between complaints, worries and random rants on the social media site and the spread of medical issues as wide-ranging as the flu, dengue fever and pollen-induced allergies.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton products in China, today reported consolidated financial results for the third quarter ended June 30, 2011.
Each year, 200,000 Americans are hospitalized due to flu-related complications.
That number can rise or fall - often dramatically - based on the effectiveness of the selected flu vaccine, said Dr. Jorge Parada, director of infection prevention and control at Loyola University Health System.
NanoViricides, Inc. recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide™, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.
Researchers have finally found the first antibody which can fight all types of the influenza A virus. The results of the experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment” for flu as well.
Social media tools like Facebook, Twitter and Foursquare may be an important key to improving the public health system's ability to prepare for, respond to, and recover from disasters, according to a New England Journal of Medicine "Perspective" article from the Perelman School of Medicine at the University of Pennsylvania to be published this week.
Aetna today announced second-quarter 2011 operating earnings of $522.8 million, or $1.35 per share, a per share increase of 29 percent over 2010.
Researchers from Australia determined that pediatric liver transplant patients who received a single-dose of the H1N1 vaccine were not adequately protected against the virus compared to healthy children.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
A final review result from Europe's drug regulatory agency released a positive link between narcolepsy and the Pandemrix 2009 H1N1 vaccine. The agency recommends a labeling change that limits the vaccine's use in children and teens to when protection is needed and seasonal trivalent vaccine isn't available.
Australia is gripped with a fourfold increase in the number of people suffering flu. This rise is even before the usual peak season in August and September. Already nearly 8,000 cases have been reported compared with about 2,000 at the same time last year. The increase has disproportionately affected Queensland, NSW and South Australia. In January and February more than 1,700 people were recorded with flu, compared with fewer than 300 the year before.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.